Plasma DNA integrity index as a potential molecular diagnostic marker for breast cancer

Tumor Biology ◽  
2015 ◽  
Vol 37 (6) ◽  
pp. 7565-7572 ◽  
Author(s):  
Azza M. Kamel ◽  
Salwa Teama ◽  
Amal Fawzy ◽  
Mervat El Deftar
Keyword(s):  
Breast Cancer ◽  
Diagnostic Marker ◽  
Molecular Diagnostic ◽  
Dna Integrity ◽  
Plasma Dna ◽  
Integrity Index

Pleural fluid DNA integrity index as a diagnostic marker of malignant pleural effusion

2017 ◽  
Vol 74 (3) ◽  
pp. 148-151 ◽  
Author(s):  
AE. Eltorgoman ◽  
EAE. Badr ◽  
YFAE. Kombr ◽  
M. Yousif
Keyword(s):  
Pleural Effusion ◽  
Pleural Fluid ◽  
Malignant Pleural Effusion ◽  
Diagnostic Marker ◽  
Dna Integrity ◽  
Integrity Index

Diagnostic relevance of plasma DNA and DNA integrity for breast cancer

Tumor Biology ◽  
2013 ◽  
Vol 35 (2) ◽  
pp. 1183-1191 ◽  
Author(s):  
Oliver J. Stötzer ◽  
Julia Lehner ◽  
Debora Fersching-Gierlich ◽  
Dorothea Nagel ◽  
Stefan Holdenrieder
Keyword(s):  
Breast Cancer ◽  
Dna Integrity ◽  
Plasma Dna

scholarly journals Exploration of the Beta-Actin DNA Integrity Index as Early Genetic Marker of Presence of Breast Cancer

2020 ◽  
Vol 17 (2) ◽  
pp. em188
Author(s):  
Ahmed AbdulJabbar Suleiman ◽  
Wafaa Hussien Habeeb ◽  
Haitham Tafash Al-Hitawee
Keyword(s):  
Breast Cancer ◽  
Genetic Marker ◽  
Dna Integrity ◽  
Beta Actin ◽  
Integrity Index

scholarly journals Plasma DNA Integrity as a Prognostic Biomarker for Colorectal Cancer Chemotherapy

2021 ◽  
Vol 2021 ◽  
pp. 1-10
Author(s):  
Feng Zhu ◽  
Jing Ma ◽  
Dongdong Ru ◽  
Ningning Wu ◽  
Yunhua Zhang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Dna Integrity ◽  
Plasma Dna ◽  
Serum Samples ◽  
Promising Candidate ◽  
Real Time Quantitative Pcr ◽  
Integrity Index ◽  
Serum Dna ◽  
Prognostic Prediction

Objectives. To verify whether the concentrations and integrity index of circulating cell-free DNA (cfDNA) in serum may be clinically useful for the progression monitoring of colorectal cancer (CRC) patients. Methods. Serum samples were collected from 76 primary CRC patients who underwent surgery, including 60 with chemotherapy and 43 with follow-up. Long (247 bp) and short (115 bp) DNA fragments in serum were detected by real-time quantitative PCR by amplifying the ALU repeats. Ten serum traditional biomarkers levels were detected by chemiluminescence immunoassay assay. Results. The median DNA integrity index (ALU247/ALU115) of serum DNA in the preoperative group was significantly higher than those in the postchemotherapy and the follow-up groups, while cfDNA concentration (ALU115) was significantly lower in the preoperative group compared with the postchemotherapy and the follow-up groups. CEA and CA242 were significantly lower in the postoperative group than in the preoperative group. Conclusions. Serum DNA integrity index (ALU247/115) may prove to be a promising candidate biomarker for prognostic prediction of CRC who underwent chemotherapy and during short-term follow-up.

scholarly journals Association of plasma DNA integrity and long fragment ALU247 in the diagnosis of epithelial ovarian cancer

2021 ◽  
pp. 35-45
Author(s):  
Feryal Farouk Sherif ◽  
Mohamed Ali El Desouky ◽  
Mona Gebril ◽  
Osama Mahmoud Azmy
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Area Under The Curve ◽  
Dna Integrity ◽  
Plasma Dna ◽  
Clinical Value ◽  
Mean Values ◽  
Integrity Index ◽  
The Mean ◽  
Healthy Females

DNA Integrity index (DNA Int) and cell-free DNA (cf-DNA) represent promising biomarkers for epithelial ovarian cancer (EOC) detection. Tumor necrosis produces DNA fractions of different sizes, which contrasts apoptosis in normal tissue that releases smaller and more regular DNA fragments. Using ALU gene primers in quantitative PCR, the amplified cf-DNA is supposed to be either short fragments of 115 bp (ALU 115) or long fragments of 247 bp (ALU 247). ALU levels and DNA Int were determined in the plasma of 30 EOC patients, 30 benign cysts, and 15 healthy individuals. The mean values of DNA Int, ALU115, and ALU247 were elevated in malignant patients (0.51±0.09, 3.93 ng/ul ±1.93, 2.35 ng/ul ±1.1) respectively in comparison to healthy females (0.37±0.05; p < 0.001, 2.56 ng/ul ±0.9; p=0.027, 1.26±0.44; p< 0.01). A significant increase was shown in the mean values of DNA Int and ALU247 of EOC patients compared to those with benign cysts (0.4±0.06, p <0.001; 1.69±0.66, p =0.008) respectively. The area under the curve (AUC) for EOC versus healthy females achieved 0.913 (DNA Int), 0.696 (ALU115), and 0.809 (ALU247) with sensitivities and specificities were (86.7% and 93.3%) for DNA Int, (63.3% and 86.7%) for ALU115 and (76.7% and 86.7%) for ALU247 respectively. Furthermore, comparing patients with EOC versus those with benign cysts gave AUC of 0.834 (DNA Int), 0.564 (ALU115), and 0.681 (ALU247) with sensitivities and specificities were (80% and 80%) for DNA Int, (63.3% and 60%) for ALU115 and (60% and 80%) for ALU247 respectively. Higher DNA Int and plasma ALU247 could help in the assessment of EOC, and their measurements seem to have clinical value in diagnosis.

Circulating plasma DNA and DNA integrity in breast cancer patients undergoing neoadjuvant chemotherapy

2013 ◽  
Vol 425 ◽  
pp. 206-211 ◽  
Author(s):  
Julia Lehner ◽  
Oliver J. Stötzer ◽  
Debora Fersching ◽  
Dorothea Nagel ◽  
Stefan Holdenrieder
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Dna Integrity ◽  
Breast Cancer Patients ◽  
Plasma Dna

Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis

2014 ◽  
Vol 146 (1) ◽  
pp. 163-174 ◽  
Author(s):  
Dharanija Madhavan ◽  
Markus Wallwiener ◽  
Karin Bents ◽  
Manuela Zucknick ◽  
Juliane Nees ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Early Diagnosis ◽  
Metastatic Breast ◽  
Dna Integrity ◽  
Plasma Dna ◽  
Potential Marker

Plasma DNA and DNA integrity in breast cancer patients undergoing neoadjuvant chemotherapy.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e21067-e21067
Author(s):  
Oliver J. Stoetzer ◽  
Holdenrieder Stefan ◽  
Julia Lehner ◽  
Deborah Fersching ◽  
Christoph Salat
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Metastatic Breast ◽  
Therapy Response ◽  
Response To Therapy ◽  
Dna Integrity ◽  
Healthy Controls ◽  
Breast Cancer Patients ◽  
Plasma Dna

e21067 Background: In breast cancer patients undergoing neoadjuvant chemotherapy before surgery, biomarkers for predicting the response to the therapy are highly needed. Methods: Concentrations of ALU115, ALU247 and DNA integrity were analyzed in prospectively collected plasma of 68 patients with localized breast cancer (UICC II and III), of 47 patients with metastatic breast cancer and 28 healthy women as controls. In all 68 patients with breast cancer who had completed the course of chemotherapy until surgery, DNA and tumor biomarkers CEA and CA 15-3 were evaluated concerning response to therapy (no change, NC: N=18; partial remission, PR: N=35; complete remission, CR: 15). Results: Plasma levels of ALU 115 and ALU 247 were significantly higher in patients with localized (medians 16.3 and 16.8 ng/mL) and metastasized breast cancer (22.2 and 29.8 ng/mL) than in healthy controls (1.8 and 1.9 ng/mL). However, plasma DNA integrity showed no significant differences between the diagnostic groups. AUCs in ROC curves for discrimination of localized breast cancer from healthy controls were 96% for ALU 115 and ALU 247, respectively, and 60% for DNA integrity. Concerning therapy response, pretherapeutic ALU 115, 247, and DNA integrity and also CEA and CA 15-3 were not significantly different when patients with and without remission (CR vs PR+NC and CR+PR vs NC) were compared. Conclusions: While plasma DNA levels are valuable for discrimination of breast cancer patients from controls, pretherapeutic DNA integrity provides no additive diagnostic information nor indicates response to neoadjuvant therapy.

Plasma DNA integrity indicates response to neoadjuvant chemotherapy in patients with locally confined breast cancer

2013 ◽  
Vol 51 (01) ◽  
pp. 59-62 ◽  
Author(s):  
Julia Lehner ◽  
Oliver J. Stötzer ◽  
Debora M.I. Fersching ◽  
Dorothea Nagel ◽  
Stefan Holdenrieder
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Dna Integrity ◽  
Plasma Dna ◽  
Response To Neoadjuvant Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document